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Introduction
Age-related hearing loss is attributed to age-related
degeneration of the cochlea as well as other physiologic,
environmental, and pathological processes that occur during the
lifespan (1). It initially affects hearing sensitivity in the high-
frequencies, affecting communication in noisy situations. Once
the loss extends to the lower frequencies (2-4 kHz range),
important for understanding the voiceless consonants, speech
understanding in any situation is affected (1). Age-related
hearing loss is a common chronic condition, affecting 30-35%
of the people aged 65-75 years and 40-50% of the people over
75 years (2).
The relationship between hearing loss and nutritional status
is a relatively new area of investigation (2). The hypothesis that
nutrition may play a role in age-related hearing loss is based on
evidence from two converging research areas: research showing
that hearing loss is related to vascular disease (3-6), and
research showing that vascular systems rely on certain nutrients
for optimal structure and function (2). Very long-chain n-3
polyunsaturated fatty acids (n-3 PUFA), as present in fish and
fish oil, are suggested to protect against vascular diseases (7).
Since the cochlea is highly vascularised, it has been suggested
that age-related hearing loss may be caused by a decrease in the
blood supply to the cochlea (5).
Very little scientific attention has been given to the potential
role of fatty acids in age-related hearing loss. A study in two
psychiatric hospitals in Finland showed that adults who
consumed a low fat diet for a period of five years had better
hearing levels throughout the entire audiometric range than
adults who consumed a diet high in saturated fatty acids (8).
However, there are currently no published studies that have
investigated the relationship between very long-chain n-3
PUFAs and age-related hearing loss. Therefore, the present
study assesses whether plasma very long-chain n-3 PUFAs are
associated with age-related hearing loss over a period of three
years in a population of Dutch older adults.
Subjects and methods
Subjects
We used data from participants of the FACIT study, a
randomized controlled trial investigating the effect of folic acid
supplementation on hearing, carotid intima-media thickness and
cognitive performance (9). In this study, 819 men and
postmenopausal women aged 50-70 years were randomly
assigned to either folic acid (n=406) or placebo (n=413)
treatment for a period of 3 years. Participants were recruited by
using municipal and local blood bank registries from the
Gelderland province in the Netherlands. Major exclusion
criteria were plasma total homocysteine levels <13 µmol/L and
>26 µmol/L, serum vitamin B12 levels <200pmol/L, renal or
thyroid diseases, and current use of B-vitamin supplements.
The baseline measurements, which included measurements of
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hearing, were conducted between 2000 and 2001. The original
study on which the present article is based was approved by the
Medical Ethics Committee of Wageningen University, the
Netherlands. All study participants provided written informed
consent.
In our analyses, subjects with middle ear dysfunction
(defined as air-bone gap ≥15 dB on the audiogram of either ear)
or unilateral hearing loss (≥20 dB difference in mean pure-tone
hearing thresholds for 0.5 kHz, 1 kHz, and 2 kHz between the
right and left ear) were excluded (n=91), as these hearing
problems are unlikely due to age-related hearing loss. In
addition, we excluded eight participants from whom
insufficient amounts of blood could be obtained or who did not
give permission for the fatty acid analyses, resulting in a total
of 720 participants.
Audiometric measurements
Excessive cerumen, if present, was removed from the
participants’ ears prior to the audiometric measurements. The
pure tone audiometric assessments were performed in an
acoustical booth (Audiofon G, Audiovox, Hauppauge, New
York), which muted sounds up to 42 dB and was placed in a
quiet, isolated, carpeted room next to the college library.
Participants were measured in seated position using an
audiometer (Madsen Voyager 522, Madsen Electronics,
Taastrup, Denmark), circum-aural earphones and a handheld
response button system. We calibrated the audiometer
according to the International Organization of Standardization
standard 389 and we performed the audiometric testing by
using a variation of the Hughson and Westlake method as
described earlier (9). Our outcomes measures are the mean
pure-tone air conduction hearing thresholds in the low (0.5-
kHz, 1-kHz, and 2-kHz) and high (4-kHz, 6-kHz, and 8-kHz)
frequencies.
To enable exclusion of participants with possible middle ear
dysfunction at the start of the study, we measured bone
conduction hearing thresholds at 0.5 kHz, 1 kHz, 2 kHz, and 4
kHz by using contra-lateral masking. To enable exclusion of
participants with unilateral hearing loss at the start of the study,
we used contra-lateral masking when the difference in air
conduction hearing threshold between the right and left ear was
50 dB or more. Subjects with a difference of 20 dB or more in
mean air conduction hearing thresholds after contra-lateral
masking between the right and left ear were excluded from the
analyses.
Plasma n-3 PUFA proportions
Venous blood was collected after an overnight fast in one
10-ml Vacutainer tube containing ethylene diamine tetra-acetic
acid (EDTA). The obtained plasma was stored within 2 hours at
-80°C until analysis. Fatty acids in plasma cholesteryl esters
were determined as described previously (10). We calculated
plasma very-long chain n-3 PUFAs by adding up the levels of
eicosapentaenoic acid (EPA), docosapentaenoic acid (n-3
DPA), and docosahexaenoic acid (DHA).
Other measurements
At baseline, participants completed a questionnaire on
general demographic variables and medical history. Height and
weight were measured to calculate body mass index (kg/m2).
Level of education was divided into three groups according to
the highest level attained: primary education, junior vocational
training and senior vocational or academic training. Blood
pressure was measured using an automated meter (Dinamap
Compact Pro 100, General Electric, Waukesha, Wisconsin) and
we took the mean of eight measurements. Serum total
cholesterol, LDL-cholesterol and HDL-cholesterol were
determined on a Hitachi® 747 analyzer (Roche Diagnostics,
Mannheim, Germany). Physical activity was estimated using
the Physical Activity Scale for the Elderly (11).
Statistical analyses
Subjects were grouped according to quartiles of plasma very
long-chain n-3 PUFA proportions. Equality of variances was
tested using Levene’s tests. Baseline characteristics of subjects
in the different quartiles were compared with chi-square tests,
one-way analysis of variance (normally distributed variables),
or Kruskal-Wallis tests (non-normally distributed variables).
Analysis of covariance (ANCOVA) was used to evaluate the
association between quartiles of plasma very long-chain n-3
PUFAs and mean hearing thresholds in the low (0.5-kHz, 1-
kHz, and 2-kHz) and high (4-kHz, 6-kHz, and 8-kHz)
frequencies. Because we excluded participants with unilateral
hearing loss, we averaged the hearing thresholds from both ears
in our outcome measures. When significant F-tests were
obtained, Tukey’s honest significant difference tests were
applied for the post hoc comparison. We evaluated age, sex,
level of education, smoking, alcohol consumption and
erythrocyte folate concentrations as potential confounders. To
investigate whether the folic acid treatment was an effect
modifier in the longitudinal analyses, we performed stratified
analysis by intervention group. Statistical significance for all
analyses was defined as p<0.05. The data analyses were
performed with the Statistical Analysis System (SAS version
9.1.3; SAS Institute Inc, Cary, NC).
Results
The mean age of our participants at baseline was 60 years
and 72% of our study population was male. When grouped
according to quartiles of plasma very long-chain n-3 PUFA,
there were no differences between the four groups in age, sex,
level of education, body mass index, smoking habits, physical
activity, blood pressure and blood parameters (Table 1).
Alcohol consumption was higher in the highest quartile of very
long-chain n-3 PUFA than in the lowest quartile. The
proportions of individual fatty acids in plasma cholesteryl
esters according to quartiles of plasma very long-chain n-3
PUFAs are shown in Table 2.
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Hearing loss over three years (longitudinal results)
We were able to analyze the data of 705 of the 720
participants in our longitudinal analyses. Fifteen participants
did not provide hearing data after three years, because they died
during the follow-up (n=11), or were lost to follow-up (n=4).
The mean increase in all participants in hearing threshold
over three years was 1.4 dB (95% CI: 1.1 to 1.7) for the low
frequencies and 4.8 dB (95% CI: 4.4 to 5.2) for the high
frequencies. Subjects in the highest quartile of very long-chain
n-3 PUFA had less hearing loss in the low frequencies over
three years than subjects in the lowest quartile (Table 3, p<0.01,
ANCOVA). The difference in the adjusted mean hearing
thresholds in the low frequencies between the highest and
lowest quartile was -1.2 dB (95%CI: -2.2 to -0.1). There were
no significant differences between the quartiles of plasma very
long-chain n-3 PUFA in mean hearing thresholds in the high
frequencies after three years (p=0.49, ANCOVA). These
longitudinal associations were adjusted for baseline mean
hearing threshold values, age, sex, level of education and
alcohol consumption.
Because we previously showed that the folic acid treatment
slowed down the decline in mean hearing threshold in the low
frequencies (9), we performed the longitudinal analyses also
separately for the placebo group and the folic acid group. When
considering the longitudinal analyses separately for the placebo
and the folic acid group, it appeared that higher proportions of
plasma very long-chain n-3 PUFA were still associated with
less hearing loss over three years in the low frequencies in the
placebo group. The difference in mean hearing threshold in the
low frequencies between the highest and lowest quartile was -
1.8 dB (95%CI -3.2 to -0.3). In the folic acid group, however,
the association was not statistically significant.
Table 1
Baseline characteristics of participants according to quartiles of plasma very long-chain n-3 PUFAsa
Characteristics Quartile 1 (n=180) Quartile 2 (n=180) Quartile 3 (n=180) Quartile 4 (n=180)
Age (y) 60.0 ± 6.0 59.8 ± 5.6 60.1 ± 5.4 60.5 ± 5.4
Gender (M/F) 140 / 40 133 / 47 122 / 58 122 / 58
Level of education (low/middle/high)b 47 / 62 / 71 44 / 66 / 70 39 / 74 / 67 34 / 68 / 78
BMI (kg/m2) 26.1 ± 3.5 26.7 ± 3.3 26.8 ± 3.8 26.8 ± 3.8
Smoking (never / former / current) 56 / 89 / 35 55 / 94 / 31 50 / 87 / 43 40 / 107 / 33
Alcohol consumption (g/day) 8.6 (1.7 – 15.7) 13.6 (4.5 – 22.3) 13.3 (5.2 – 26.5) 17.2 (7.6 – 27.5)
Physical Activity (PASE score) 150 ± 71 163 ± 68 155 ± 73 145 ± 61
Self-reported hearing problems 16 21 17 19
Serum total cholesterol (mmol/L) 5.64 ± 0.99 5.76 ± 1.11 5.97 ± 1.02 5.91 ± 1.17
Serum LDL cholesterol (mmol/L)c 3.87 ± 0.87 3.96 ± 0.97 4.13 ± 0.91 4.07 ± 1.02
Serum HDL cholesterol (mmol/L) 1.23 ± 0.32 1.21 ± 0.34 1.23 ± 0.35 1.28 ± 0.40
Systolic blood pressure (mm Hg)d 132 ± 16 132 ± 16 134 ± 17 133 ± 15
Diastolic blood pressure (mm Hg)d 77 ± 8 77 ± 9 77 ± 8 77 ± 8
Values are means ± SD, medians (interquartile range) or n. a. Plasma very long-chain n-3 PUFA quartiles 1: <1.18%; 2: 1.18-1.51%; 3: 1.52-2.04%; 4: >2.04%. b. Low=primary
education; Middle=junior vocational training; High= senior vocational or academic training. c. Data available for 718 participants. d. Data available for 716 participants.
Table 2
Fatty acid contents (% of total fatty acids) in plasma cholesteryl esters according to quartiles of plasma very long-chain
n-3 PUFAsa
Fatty acids Quartile 1 (n=180) Quartile 2 (n=180) Quartile 3 (n=180) Quartile 4 (n=180)
Saturated fatty acids, total 12.2 ± 1.1 12.9 ± 1.2 13.0 ± 1.1 13.2 ± 1.0
Palmitic acid, 16:0 10.5 ± 0.8 11.0 ± 0.9 11.1 ± 0.9 11.3 ± 0.8
Stearic acid, 18:0 0.8 ± 0.2 0.8 ± 0.2 0.8 ± 0.2 0.8 ± 0.2
N-9 mono-unsaturated fatty acids, total 16.3 ± 2.2 17.0 ± 2.3 17.4 ± 2.3 17.8 ± 2.2
Oleic acid, 18:1n-9 16.3 ± 2.2 17.0 ± 2.3 17.4 ± 2.3 17.8 ± 2.2
N-6 polyunsaturated fatty acids, total 64.8 ± 3.9 62.4 ± 4.1 61.2 ± 4.3 59.3 ± 4.1
Linoleic acid, 18:2n-6 57.2 ± 4.2 53.8 ± 4.7 52.6 ± 4.9 50.9 ± 4.5
Arachidonic acid, 20:4n-6 6.0 ± 1.5 6.9 ± 1.4 6.9 ± 1.4 6.8 ± 1.3
N-3 polyunsaturated fatty acids, total 1.6 ± 0.2 2.0 ± 0.2 2.3 ± 0.2 3.4 ± 0.9
-Linolenic acid, 18:3n-3 0.6 ± 0.2 0.6 ± 0.1 0.6 ± 0.1 0.6 ± 0.1
Eicosapentaenoic acid, 20:5n-3 0.6 ± 0.1 0.8 ± 0.1 1.1 ± 0.2 2.0 ± 0.8
Docosapentaenoic acid, 22:5n-3 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
Docosahexaenoic acid, 22:6n-3 0.4 ± 0.1 0.5 ± 0.1 0.6 ± 0.1 0.8 ± 0.2
Values are means (SD). a. Plasma very long-chain n-3 PUFA quartiles 1: <1.18%; 2: 1.18-1.51%; 3: 1.52-2.04%; 4: >2.04%.
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Because the study by Rosen et al. (8) reported worse hearing
thresholds in persons on a saturated fat diet compared with
persons on a low fat diet, we also evaluated the associations
between plasma saturated fatty acids and mean hearing
thresholds (data not shown). However, there were no
significant differences between the quartiles of plasma
saturated fatty acids in mean hearing thresholds in the low or
high frequencies after three years (p=0.46 and p=0.29 for
ANCOVA, respectively).
Hearing thresholds (cross-sectional results)
There were no significant differences between the four
quartiles of plasma very long-chain n-3 PUFA in the mean
hearing threshold at baseline in the low frequencies (Q1
(Quartile 1): 13.5 (95%CI: 12.1 to 14.8); Q2: 14.6 (95%CI:
13.3 to 15.9); Q3: 13.8 (95%CI: 12.5 to 15.1); Q4: 12.6
(95%CI: 11.3 to 13.9; p=0.21 for ANCOVA), after adjustments
for age, sex, and education level. In addition, no significant
differences between the quartiles were found in the mean
hearing threshold in the high frequencies (Q1: 36.9 (95%CI:
34.5 to 39.3); Q2: 38.1 (95%CI: 35.7 to 40.5); Q3: 39.5
(95%CI: 37.1 to 41.9); Q4: 35.4 (95%CI: 33.0 to 37.9); p=0.12
for ANCOVA), after adjustments for the same confounders.
Mean hearing thresholds in the low and high frequencies
were not significantly different between quartiles of plasma
saturated fatty acids (p=0.36 and p=0.54 for ANCOVA,
respectively), although the results were in the expected
direction. Mean hearing thresholds on the low and high
frequencies tended to be higher for the highest quartile of
saturated fatty acids, compared with the lowest quartile of
saturated fatty acids (data not shown).
Discussion
The present study in older adults shows that people in the
highest quartile of plasma very long-chain n-3 PUFAs had less
hearing loss in the low frequencies over three years than people
in the lowest quartile. Plasma very long-chain n-3 PUFAs
appeared not to be associated with hearing loss in the high
frequencies.
The hearing loss in our study population was likely to be
age-related hearing loss of cochlear origin. By excluding
participants with middle-ear dysfunction and unilateral hearing
loss from our study population, we aimed to exclude
participants with altered hearing thresholds due to conductive
hearing loss or noise-induced hearing damage.
Rosen et al. were the first to investigate whether a change in
diet affects hearing loss in older adults (40-60 y). They showed
better hearing in subjects receiving a low-fat diet and
worsening of hearing in subjects receiving a diet high in
saturated fat (8). In contrast, we did not show significant
differences between quartiles of saturated fatty acids. However,
one has to keep in mind that plasma saturated fatty acids can
not provide direct information on absolute saturated fat intake.
Although plasma saturated fatty acids are dependent on their
absolute concentrations and relative proportions in food, they
also include endogenously synthesized saturated fatty acids
(12).
Our analyses are the first to show an inverse relationship
between plasma very long-chain n-3 PUFA proportions and
age-related hearing loss in older adults. This study has several
strengths, including a longitudinal design, the use of plasma
proportions of very long-chain n-3 PUFA as a valid estimate of
dietary intake of fatty acids (13) and sound audiometric
assessments under standardized test conditions. Nevertheless,
several issues should be addressed to enable a balanced
interpretation of the findings.
First, plasma very long-chain n-3 PUFAs were associated
with hearing loss in the low frequencies, but not significantly
with hearing loss in the high frequencies. The apex of the
cochlea transduces the low-frequencies sounds, whereas the
base of the cochlea is responsible for the transduction of the
high-frequencies sounds. Since the inner ear is an end organ
and is only supplied by one or sometimes two arteries (14),
microvascular disease could affect the blood supply to the
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Table 3
Hearing thresholds in the low and high frequencies after 3 years according to quartiles of plasma very long-chain n-3 PUFAsa
Quartile 1 Quartile 2 Quartile 3 Quartile 4 P-valueb
All participants
Sample size, n 176 177 175 177
Hearing threshold on low frequencies, dB 15.7 (15.1; 16.2)c 15.4 (14.8; 15.9)cd 14.6 (14.1; 15.2)d 14.5 (14.0; 15.1)d <0.01
Hearing threshold on high frequencies, dB 42.4 (41.5; 43.3) 42.6 (41.8; 43.5) 41.7 (40.8; 42.6) 42.2 (41.3; 43.1) 0.49
Placebo group only
Sample size, n 91 90 90 91
Hearing threshold on low frequencies, dB 16.1 (15.3; 16.8)c 15.5 (14.7; 16.2)cd 14.8 (14.1; 15.5)cd 14.3 (13.6; 15.1)d <0.01
Hearing threshold on high frequencies, dB 42.5 (41.3; 43.8) 43.4 (42.2; 44.6) 42.5 (41.3; 43.7) 42.3 (41.1; 43.5) 0.58
Folic acid group only
Sample size, n 85 87 86 85
Hearing threshold on low frequencies, dB 15.1 (14.3; 15.9) 15.4 (14.7; 16.2) 14.4 (13.6; 15.2) 14.7 (13.9; 15.5) 0.31
Hearing threshold on high frequencies, dB 42.0 (40.8; 43.3) 42.1 (40.8; 43.4) 40.9 (39.6; 42.2) 42.0 (40.7; 43.3) 0.51
Results are adjusted means (95% CI); dB=decibel. a. Plasma very long-chain n-3 PUFA quartiles 1: <1.18%; 2: 1.18-1.51%; 3: 1.52-2.04%; 4: >2.04% (all participants). b. ANCOVA
adjusted for baseline mean hearing threshold, age, sex, level of education and alcohol consumption. Post-hoc comparison by Tukey’s Honest Significant Differences test (means in a row
with different superscript letters are significantly different).
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cochlea. As the apex of the cochlea is the farthest away from
the blood supply, it may be most susceptible to changes in the
microcirculation (15), and therefore particularly affect hearing
thresholds on the low frequencies (3). An improvement in
microcirculation may explain the association of plasma very
long-chain n-3 PUFAs with low-frequency thresholds.
Alternatively, more variation in the hearing threshold in the
high frequencies compared with the low frequencies, may
explain why we did not detect a significant difference between
very long-chain n-3 PUFA quartiles and hearing thresholds on
the high-frequencies with the current study sample size.
A second study-related issue that needs to be addressed is
that half of our participants received folic acid supplementation
for three years, because our study population originally
participated in a randomized controlled trial. This folic acid
treatment has been shown to slow down the decline in hearing
in the low frequencies (9). Our stratified analyses show that
higher proportions of plasma very long-chain n-3 PUFA
were still associated with less hearing loss in the low
frequencies in the placebo group, but not in the folic acid
group. Although the mean hearing thresholds in the folic acid
group were not significantly different across the quartiles, the
results were in the expected direction. This suggests that the
treatment effect of folic acid overruled a potential association
between plasma very long-chain n-3 PUFA and hearing loss in
the folic acid group.
A third issue is the apparent inconsistency between the
cross-sectional and the longitudinal results. Because our study
population consisted of relatively young subjects (mean age: 60
yrs), it could well be that hearing disabilities are just beginning
to develop in our participants. This corresponds with our
findings that subjects with higher mean hearing thresholds at
the start of the study also had a faster threshold increase than
subjects with lower mean hearing thresholds at baseline.
Two other issues that require attention are the actual
difference in hearing loss between the quartiles and the range of
plasma very long-chain n-3 PUFAs. The difference in hearing
loss between the highest and the lowest quartile of plasma very
long-chain n-3 PUFAs appears to be small: -1.2 dB for the
whole study population and -1.8 dB when only the placebo
group was considered. However, since hearing loss increases
over time and since our study population was relatively young,
the difference between the quartiles could be greater in older
populations. This is supported by our findings of a difference in
hearing loss between the highest en lowest quartile of -0.8 dB
in subjects of 50-60 yrs, and -1.5 dB in subjects of 60-70 yrs.
Moreover, although the range of plasma very long-chain n-3
PUFA proportions in our study population was similar to that
of other large studies in older adult populations (12, 16), it
could be possible that the differences in hearing loss between
the quartiles become even more pronounced if this range would
have been wider.
Finally, it is important to realise that our study population
may not represent a random sample of the Dutch older adult
population, because our subjects were selected on the basis for
participation in a randomized controlled trial (e.g. moderate
levels of homocysteine, no vitamin B12 deficiency, no lipid-
lowering drugs). This may affect the generalizability of our
results.
In summary, these analyses provide us with encouraging
results on an inverse association between very long-chain n-3
PUFAs and hearing loss. These results require confirmation
from future observational studies to verify the direction, size
and importance of the reported associations.
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